Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).
Identifieur interne : 000150 ( Main/Exploration ); précédent : 000149; suivant : 000151Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).
Auteurs : Michael Sandherr [Allemagne] ; Marcus Hentrich ; Marie Von Lilienfeld-Toal ; Gero Massenkeil ; Silke Neumann ; Olaf Penack ; Lena Biehl ; Oliver A. CornelySource :
- Annals of hematology [ 1432-0584 ] ; 2015.
Descripteurs français
- KwdFr :
- Allemagne (MeSH), Antinéoplasiques (usage thérapeutique), Antiviraux (usage thérapeutique), Autogreffes (MeSH), Femelle (MeSH), Guides de bonnes pratiques cliniques comme sujet (MeSH), Humains (MeSH), Hématologie (MeSH), Leucémies (thérapie), Maladie aigüe (MeSH), Maladies virales (prévention et contrôle), Mâle (MeSH), Oncologie médicale (MeSH), Sociétés médicales (MeSH), Transplantation de cellules souches (MeSH), Tumeurs du sein (thérapie).
- MESH :
- prévention et contrôle : Maladies virales.
- thérapie : Leucémies, Tumeurs du sein.
- usage thérapeutique : Antinéoplasiques, Antiviraux.
- Allemagne, Autogreffes, Femelle, Guides de bonnes pratiques cliniques comme sujet, Humains, Hématologie, Maladie aigüe, Mâle, Oncologie médicale, Sociétés médicales, Transplantation de cellules souches.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Acute Disease (MeSH), Antineoplastic Agents (therapeutic use), Antiviral Agents (therapeutic use), Autografts (MeSH), Breast Neoplasms (therapy), Female (MeSH), Germany (MeSH), Hematology (MeSH), Humans (MeSH), Leukemia (therapy), Male (MeSH), Medical Oncology (MeSH), Practice Guidelines as Topic (MeSH), Societies, Medical (MeSH), Stem Cell Transplantation (MeSH), Virus Diseases (prevention & control).
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Antiviral Agents.
- geographic : Germany.
- prevention & control : Virus Diseases.
- therapy : Breast Neoplasms, Leukemia.
- Acute Disease, Autografts, Female, Hematology, Humans, Male, Medical Oncology, Practice Guidelines as Topic, Societies, Medical, Stem Cell Transplantation.
Abstract
Reactivation of viral infections is common in patients with solid tumour or haematological malignancy. Incidence and severity depend on the extent of cellular immunosuppression. Antiviral prophylaxis may be effective to prevent viral reactivation. In 2006, the Infectious Diseases Working Party of German Society for Hematology and Medical Oncology (DGHO) published guidelines for antiviral prophylaxis in these patient populations. Here, we present an update of these guidelines for patients with solid and haematological malignancies undergoing antineoplastic treatment but not allogeneic stem cell transplantation. Relevant literature for reactivation of different viruses (herpes simplex virus (HSV), varicella zoster virus (VZV), hepatitis B virus (HBV) and respiratory viruses) is discussed to provide evidence-based recommendations for clinicians taking care of this patient population. We recommend a risk-adapted approach with (val)acyclovir against HSV and VZV in patients treated with alemtuzumab, bortezomib or purine analogues. Seasonal vaccination against influenza is recommended for all patients with solid or haematological malignancies regardless of antineoplastic therapy. Hepatitis B screening is recommended in lymphoproliferative disorders, acute leukaemia, and breast cancer, and during treatment with monoclonal anti-B-cell antibodies, anthracyclines, steroids and in autologous stem cell transplantation. In those with a history of hepatitis B prophylactic lamivudine, entecavir or nucleotide analogues as adefovir are recommended to prevent reactivation.
DOI: 10.1007/s00277-015-2447-3
PubMed: 26193852
PubMed Central: PMC4525190
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).</title><author><name sortKey="Sandherr, Michael" sort="Sandherr, Michael" uniqKey="Sandherr M" first="Michael" last="Sandherr">Michael Sandherr</name><affiliation wicri:level="1"><nlm:affiliation>Gemeinschaftspraxis für Hämatologie und Onkologie, Röntgenstr. 4, 82362, Weilheim, Germany, michael.sandherr@web.de.</nlm:affiliation><country wicri:rule="url">Allemagne</country><wicri:regionArea>Gemeinschaftspraxis für Hämatologie und Onkologie, Röntgenstr. 4, 82362, Weilheim, Germany</wicri:regionArea><wicri:noRegion>Germany</wicri:noRegion><wicri:noRegion>Germany</wicri:noRegion><wicri:noRegion>Germany</wicri:noRegion></affiliation></author><author><name sortKey="Hentrich, Marcus" sort="Hentrich, Marcus" uniqKey="Hentrich M" first="Marcus" last="Hentrich">Marcus Hentrich</name></author><author><name sortKey="Von Lilienfeld Toal, Marie" sort="Von Lilienfeld Toal, Marie" uniqKey="Von Lilienfeld Toal M" first="Marie" last="Von Lilienfeld-Toal">Marie Von Lilienfeld-Toal</name></author><author><name sortKey="Massenkeil, Gero" sort="Massenkeil, Gero" uniqKey="Massenkeil G" first="Gero" last="Massenkeil">Gero Massenkeil</name></author><author><name sortKey="Neumann, Silke" sort="Neumann, Silke" uniqKey="Neumann S" first="Silke" last="Neumann">Silke Neumann</name></author><author><name sortKey="Penack, Olaf" sort="Penack, Olaf" uniqKey="Penack O" first="Olaf" last="Penack">Olaf Penack</name></author><author><name sortKey="Biehl, Lena" sort="Biehl, Lena" uniqKey="Biehl L" first="Lena" last="Biehl">Lena Biehl</name></author><author><name sortKey="Cornely, Oliver A" sort="Cornely, Oliver A" uniqKey="Cornely O" first="Oliver A" last="Cornely">Oliver A. Cornely</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26193852</idno><idno type="pmid">26193852</idno><idno type="doi">10.1007/s00277-015-2447-3</idno><idno type="pmc">PMC4525190</idno><idno type="wicri:Area/Main/Corpus">000126</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000126</idno><idno type="wicri:Area/Main/Curation">000126</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000126</idno><idno type="wicri:Area/Main/Exploration">000126</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).</title><author><name sortKey="Sandherr, Michael" sort="Sandherr, Michael" uniqKey="Sandherr M" first="Michael" last="Sandherr">Michael Sandherr</name><affiliation wicri:level="1"><nlm:affiliation>Gemeinschaftspraxis für Hämatologie und Onkologie, Röntgenstr. 4, 82362, Weilheim, Germany, michael.sandherr@web.de.</nlm:affiliation><country wicri:rule="url">Allemagne</country><wicri:regionArea>Gemeinschaftspraxis für Hämatologie und Onkologie, Röntgenstr. 4, 82362, Weilheim, Germany</wicri:regionArea><wicri:noRegion>Germany</wicri:noRegion><wicri:noRegion>Germany</wicri:noRegion><wicri:noRegion>Germany</wicri:noRegion></affiliation></author><author><name sortKey="Hentrich, Marcus" sort="Hentrich, Marcus" uniqKey="Hentrich M" first="Marcus" last="Hentrich">Marcus Hentrich</name></author><author><name sortKey="Von Lilienfeld Toal, Marie" sort="Von Lilienfeld Toal, Marie" uniqKey="Von Lilienfeld Toal M" first="Marie" last="Von Lilienfeld-Toal">Marie Von Lilienfeld-Toal</name></author><author><name sortKey="Massenkeil, Gero" sort="Massenkeil, Gero" uniqKey="Massenkeil G" first="Gero" last="Massenkeil">Gero Massenkeil</name></author><author><name sortKey="Neumann, Silke" sort="Neumann, Silke" uniqKey="Neumann S" first="Silke" last="Neumann">Silke Neumann</name></author><author><name sortKey="Penack, Olaf" sort="Penack, Olaf" uniqKey="Penack O" first="Olaf" last="Penack">Olaf Penack</name></author><author><name sortKey="Biehl, Lena" sort="Biehl, Lena" uniqKey="Biehl L" first="Lena" last="Biehl">Lena Biehl</name></author><author><name sortKey="Cornely, Oliver A" sort="Cornely, Oliver A" uniqKey="Cornely O" first="Oliver A" last="Cornely">Oliver A. Cornely</name></author></analytic><series><title level="j">Annals of hematology</title><idno type="eISSN">1432-0584</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Disease (MeSH)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Autografts (MeSH)</term><term>Breast Neoplasms (therapy)</term><term>Female (MeSH)</term><term>Germany (MeSH)</term><term>Hematology (MeSH)</term><term>Humans (MeSH)</term><term>Leukemia (therapy)</term><term>Male (MeSH)</term><term>Medical Oncology (MeSH)</term><term>Practice Guidelines as Topic (MeSH)</term><term>Societies, Medical (MeSH)</term><term>Stem Cell Transplantation (MeSH)</term><term>Virus Diseases (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne (MeSH)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Autogreffes (MeSH)</term><term>Femelle (MeSH)</term><term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Hématologie (MeSH)</term><term>Leucémies (thérapie)</term><term>Maladie aigüe (MeSH)</term><term>Maladies virales (prévention et contrôle)</term><term>Mâle (MeSH)</term><term>Oncologie médicale (MeSH)</term><term>Sociétés médicales (MeSH)</term><term>Transplantation de cellules souches (MeSH)</term><term>Tumeurs du sein (thérapie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term><term>Leukemia</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Leucémies</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Acute Disease</term><term>Autografts</term><term>Female</term><term>Hematology</term><term>Humans</term><term>Male</term><term>Medical Oncology</term><term>Practice Guidelines as Topic</term><term>Societies, Medical</term><term>Stem Cell Transplantation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Allemagne</term><term>Autogreffes</term><term>Femelle</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Hématologie</term><term>Maladie aigüe</term><term>Mâle</term><term>Oncologie médicale</term><term>Sociétés médicales</term><term>Transplantation de cellules souches</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Reactivation of viral infections is common in patients with solid tumour or haematological malignancy. Incidence and severity depend on the extent of cellular immunosuppression. Antiviral prophylaxis may be effective to prevent viral reactivation. In 2006, the Infectious Diseases Working Party of German Society for Hematology and Medical Oncology (DGHO) published guidelines for antiviral prophylaxis in these patient populations. Here, we present an update of these guidelines for patients with solid and haematological malignancies undergoing antineoplastic treatment but not allogeneic stem cell transplantation. Relevant literature for reactivation of different viruses (herpes simplex virus (HSV), varicella zoster virus (VZV), hepatitis B virus (HBV) and respiratory viruses) is discussed to provide evidence-based recommendations for clinicians taking care of this patient population. We recommend a risk-adapted approach with (val)acyclovir against HSV and VZV in patients treated with alemtuzumab, bortezomib or purine analogues. Seasonal vaccination against influenza is recommended for all patients with solid or haematological malignancies regardless of antineoplastic therapy. Hepatitis B screening is recommended in lymphoproliferative disorders, acute leukaemia, and breast cancer, and during treatment with monoclonal anti-B-cell antibodies, anthracyclines, steroids and in autologous stem cell transplantation. In those with a history of hepatitis B prophylactic lamivudine, entecavir or nucleotide analogues as adefovir are recommended to prevent reactivation. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26193852</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0584</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>9</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of hematology</Title><ISOAbbreviation>Ann. Hematol.</ISOAbbreviation></Journal><ArticleTitle>Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).</ArticleTitle><Pagination><MedlinePgn>1441-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00277-015-2447-3</ELocationID><Abstract><AbstractText>Reactivation of viral infections is common in patients with solid tumour or haematological malignancy. Incidence and severity depend on the extent of cellular immunosuppression. Antiviral prophylaxis may be effective to prevent viral reactivation. In 2006, the Infectious Diseases Working Party of German Society for Hematology and Medical Oncology (DGHO) published guidelines for antiviral prophylaxis in these patient populations. Here, we present an update of these guidelines for patients with solid and haematological malignancies undergoing antineoplastic treatment but not allogeneic stem cell transplantation. Relevant literature for reactivation of different viruses (herpes simplex virus (HSV), varicella zoster virus (VZV), hepatitis B virus (HBV) and respiratory viruses) is discussed to provide evidence-based recommendations for clinicians taking care of this patient population. We recommend a risk-adapted approach with (val)acyclovir against HSV and VZV in patients treated with alemtuzumab, bortezomib or purine analogues. Seasonal vaccination against influenza is recommended for all patients with solid or haematological malignancies regardless of antineoplastic therapy. Hepatitis B screening is recommended in lymphoproliferative disorders, acute leukaemia, and breast cancer, and during treatment with monoclonal anti-B-cell antibodies, anthracyclines, steroids and in autologous stem cell transplantation. In those with a history of hepatitis B prophylactic lamivudine, entecavir or nucleotide analogues as adefovir are recommended to prevent reactivation. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sandherr</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gemeinschaftspraxis für Hämatologie und Onkologie, Röntgenstr. 4, 82362, Weilheim, Germany, michael.sandherr@web.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hentrich</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>von Lilienfeld-Toal</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Massenkeil</LastName><ForeName>Gero</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Silke</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Penack</LastName><ForeName>Olaf</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Biehl</LastName><ForeName>Lena</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Cornely</LastName><ForeName>Oliver A</ForeName><Initials>OA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Ann Hematol</MedlineTA><NlmUniqueID>9107334</NlmUniqueID><ISSNLinking>0939-5555</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064592" MajorTopicYN="N">Autografts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006405" MajorTopicYN="N">Hematology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007938" MajorTopicYN="N">Leukemia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="N">Medical Oncology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26193852</ArticleId><ArticleId IdType="doi">10.1007/s00277-015-2447-3</ArticleId><ArticleId IdType="pmc">PMC4525190</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Oncol. 2010 Jul 1;28(19):3199-202</Citation><ArticleIdList><ArticleId IdType="pubmed">20516452</ArticleId></ArticleIdList></Reference><Reference><Citation>Transpl Infect Dis. 2013 Jun;15(3):219-32</Citation><ArticleIdList><ArticleId IdType="pubmed">23363310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2011 Sep;22 Suppl 6:vi59-63</Citation><ArticleIdList><ArticleId IdType="pubmed">21908506</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015;10(5):e0126037</Citation><ArticleIdList><ArticleId IdType="pubmed">25973905</ArticleId></ArticleIdList></Reference><Reference><Citation>Therap Adv Gastroenterol. 2012 Sep;5(5):359-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22973419</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2004 Apr 5;90(7):1306-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15054446</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2003 May 15;97(10):2576-87</Citation><ArticleIdList><ArticleId IdType="pubmed">12733157</ArticleId></ArticleIdList></Reference><Reference><Citation>Haematologica. 2014 Feb;99(2):232-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24497560</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2012 Sep 10;30(26):3167-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22711851</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2009 Aug;10(8):816-24</Citation><ArticleIdList><ArticleId IdType="pubmed">19647202</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2013 May 28;108(10):1931-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23652302</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2001 Mar 15;32(6):851-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11247707</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2006 Jul;17(7):1051-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16410361</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2001 Feb 1;32(3):391-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11170946</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cancer. 2009 Dec;45(18):3131-48</Citation><ArticleIdList><ArticleId IdType="pubmed">19796930</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Anticancer Ther. 2006 Aug;6(8):1175-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16925484</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2009 Apr 2;113(14):3147-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19144986</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2015 Aug 6;126(6):739-45</Citation><ArticleIdList><ArticleId IdType="pubmed">26059948</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2014 Nov 20;32(33):3736-43</Citation><ArticleIdList><ArticleId IdType="pubmed">25287829</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2010 May 10;28(14):2481-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20385981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2008 Oct;9(10):982-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19071255</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Hematol Oncol. 2014 Jan 28;3(1):4</Citation><ArticleIdList><ArticleId IdType="pubmed">24472371</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Anti Infect Ther. 2014 Feb;12(2):151-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24341369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatology. 2009 May;49(5 Suppl):S35-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19399812</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2013 Dec 12;122(25):4047-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24174625</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunotherapy. 2009 Nov;1(6):1053-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20635919</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1999 Dec 15;94(12):4029-35</Citation><ArticleIdList><ArticleId IdType="pubmed">10590046</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Clin Oncol. 2011 Jul;41(7):876-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21616919</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ther. 2016 Jan-Feb;23 (1):e300-3</Citation><ArticleIdList><ArticleId IdType="pubmed">24368609</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Mar;83(6):1627-31</Citation><ArticleIdList><ArticleId IdType="pubmed">3006059</ArticleId></ArticleIdList></Reference><Reference><Citation>J Support Oncol. 2012 Jul-Aug;10(4):155-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22222250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25447850</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2013 Aug 1;31(22):2765-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23775967</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2013;10:CD008983</Citation><ArticleIdList><ArticleId IdType="pubmed">24166741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2009 Feb 1;27(4):605-11</Citation><ArticleIdList><ArticleId IdType="pubmed">19075267</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2003 Aug;70(4):553-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12794717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Hematol. 2012 Aug;91(8):1161-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22638755</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2000 Nov;62(3):299-307</Citation><ArticleIdList><ArticleId IdType="pubmed">11055239</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2011 Feb 15;104(4):559-63</Citation><ArticleIdList><ArticleId IdType="pubmed">21285992</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res. 2015 Feb;39(2):151-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25524176</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Haematol. 1984 Oct;13(3):645-60</Citation><ArticleIdList><ArticleId IdType="pubmed">6094062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatology. 2003 Jun;37(6):1320-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12774010</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1997 Jun;15(6):2269-74</Citation><ArticleIdList><ArticleId IdType="pubmed">9196140</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2008 Oct 10;26(29):4784-90</Citation><ArticleIdList><ArticleId IdType="pubmed">18711175</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2010 Dec;21(12):2301-3</Citation><ArticleIdList><ArticleId IdType="pubmed">20616196</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2009 Jan 1;115(1):229-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19090004</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Oncol. 2002;19(2):71-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12180483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1998 Oct 1;129(7):559-66</Citation><ArticleIdList><ArticleId IdType="pubmed">9758577</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Infect Dis. 2001 Aug;14(4):409-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11964857</ArticleId></ArticleIdList></Reference><Reference><Citation>Liver Int. 2011 Mar;31(3):330-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20738779</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Med Res. 2005 Nov;3(4):214-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16303886</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Feb 18;115(7):1331-42</Citation><ArticleIdList><ArticleId IdType="pubmed">20009037</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncologist. 2011;16(5):579-84</Citation><ArticleIdList><ArticleId IdType="pubmed">21464465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2012 Feb;23(2):450-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21576285</ArticleId></ArticleIdList></Reference><Reference><Citation>Support Care Cancer. 2012 Nov;20(11):2999-3008</Citation><ArticleIdList><ArticleId IdType="pubmed">22933131</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2012 Feb;156(4):446-67</Citation><ArticleIdList><ArticleId IdType="pubmed">22211428</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Disord Drug Targets. 2011 Feb;11(1):27-33</Citation><ArticleIdList><ArticleId IdType="pubmed">21303338</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hepatol. 2012 Jul;57(1):167-85</Citation><ArticleIdList><ArticleId IdType="pubmed">22436845</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Hepatol. 2015 Jun 8;7(10):1377-89</Citation><ArticleIdList><ArticleId IdType="pubmed">26052383</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 1984 Jul;50(1):45-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6378236</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2004 Mar 1;103(5):1611-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14525792</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2013 Feb 20;31(6):794-810</Citation><ArticleIdList><ArticleId IdType="pubmed">23319691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2009 May;43(10):757-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19043458</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Lymphoma Myeloma. 2009 Apr;9(2):151-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19406726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2010 Dec;21(12):2333-41</Citation><ArticleIdList><ArticleId IdType="pubmed">20511340</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 2013 Jul;54(7):1387-95</Citation><ArticleIdList><ArticleId IdType="pubmed">23240909</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2009 Aug;9(8):493-504</Citation><ArticleIdList><ArticleId IdType="pubmed">19628174</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Immunol. 2013 Aug;32(4):358-76</Citation><ArticleIdList><ArticleId IdType="pubmed">23617253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wien Med Wochenschr. 2004 May;154(9-10):209-17</Citation><ArticleIdList><ArticleId IdType="pubmed">15244046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2011 Jun;70(6):886-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21378403</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Compr Canc Netw. 2012 Nov 1;10(11):1412-45</Citation><ArticleIdList><ArticleId IdType="pubmed">23138169</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Treat Options Oncol. 2014 Jun;15(2):210-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24570331</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2007 Mar;136(5):699-712</Citation><ArticleIdList><ArticleId IdType="pubmed">17338776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2011 May;22(5):1170-80</Citation><ArticleIdList><ArticleId IdType="pubmed">21115603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2011 Jun;70(6):909-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21378402</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncology. 2012;82(2):126-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22414954</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Res Treat. 2013 Sep;141(2):167-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24002736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2011 Sep;22(9):2031-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21303799</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Compr Canc Netw. 2012 Nov 1;10(11):1447-54; quiz 1454</Citation><ArticleIdList><ArticleId IdType="pubmed">23138170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematology Am Soc Hematol Educ Program. 2003;:438-72</Citation><ArticleIdList><ArticleId IdType="pubmed">14633794</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 2010 Jul 30;70(11):1445-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20614951</ArticleId></ArticleIdList></Reference><Reference><Citation>Transpl Infect Dis. 2011 Oct;13(5):480-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21615848</ArticleId></ArticleIdList></Reference><Reference><Citation>Dig Liver Dis. 2011 Jan;43 Suppl 1:S49-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21195372</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 2002 Oct;36(10):1525-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12243600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2014 Jun;25(6):1243-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24618150</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2003 Jan;31(1):51-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12621507</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Disord Drug Targets. 2011 Feb;11(1):34-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21303339</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Compr Canc Netw. 2011 May;9(5):484-560</Citation><ArticleIdList><ArticleId IdType="pubmed">21550968</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Biehl, Lena" sort="Biehl, Lena" uniqKey="Biehl L" first="Lena" last="Biehl">Lena Biehl</name><name sortKey="Cornely, Oliver A" sort="Cornely, Oliver A" uniqKey="Cornely O" first="Oliver A" last="Cornely">Oliver A. Cornely</name><name sortKey="Hentrich, Marcus" sort="Hentrich, Marcus" uniqKey="Hentrich M" first="Marcus" last="Hentrich">Marcus Hentrich</name><name sortKey="Massenkeil, Gero" sort="Massenkeil, Gero" uniqKey="Massenkeil G" first="Gero" last="Massenkeil">Gero Massenkeil</name><name sortKey="Neumann, Silke" sort="Neumann, Silke" uniqKey="Neumann S" first="Silke" last="Neumann">Silke Neumann</name><name sortKey="Penack, Olaf" sort="Penack, Olaf" uniqKey="Penack O" first="Olaf" last="Penack">Olaf Penack</name><name sortKey="Von Lilienfeld Toal, Marie" sort="Von Lilienfeld Toal, Marie" uniqKey="Von Lilienfeld Toal M" first="Marie" last="Von Lilienfeld-Toal">Marie Von Lilienfeld-Toal</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Sandherr, Michael" sort="Sandherr, Michael" uniqKey="Sandherr M" first="Michael" last="Sandherr">Michael Sandherr</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000150 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000150 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26193852
|texte= Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26193852" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |